Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease

Completed · Phase 1

Conditions studied: Heart Failure

In brief

The purpose of this study is to determine the effects of CLP, with and without spironolactone, on serum, urine, and fecal contents in heart failure patients with chronic kidney disease.

Key facts

Study ID

NCT01598740

Run by

Sorbent Therapeutics

People needed

18

Starts

2012-06-01

Expected to finish

2012-09-01

Last updated by the study team

2013-07-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Heart failure with New York Heart Association (NYHA) Classification II or III
• Chronic kidney disease
• Cardiac ejection fraction <40%
• On heart failure therapy including an ACEI or ARB, and a BB
• Willing to understand and comply with study procedures and provide written informed consent.

You may not qualify if…

• Hospitalization within 4 weeks of baseline visit
• History or presence of gastrointestinal conditions such as severe constipation or gastrointestinal tract strictures
• Current or anticipated dialysis during study
• In the investigator's judgment, any cardiovascular, renal, hepatic, endocrine, gastrointestinal, neurological, or other disease or condition that makes the subject's study participation unsafe
• Drug or alcohol abuse

Where it is running

• Orange Country Research Center — Tustin, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.